LEROCHOL
Launchlerodalcibep-liga
BLAINJECTIONINJECTABLE
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LEROCHOL (lerodalcibep-liga) is lerodalcibep-liga is a recombinant fusion protein that binds pcsk9 with picomolar affinity. First approved in 2025.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEROCHOL (lerodalcibep-liga) is a recombinant fusion protein that inhibits PCSK9 to increase hepatic LDL receptor availability and lower LDL-C. It is indicated for hypercholesterolemia management in patients requiring additional LDL-C reduction. The drug represents a novel mechanism within the PCSK9 inhibitor class, offering an alternative to monoclonal antibodies.
Launch
Launch-stage asset with moderate competitive pressure (30%) suggests active commercial build and team expansion opportunity.
Mechanism of Action
Lerodalcibep-liga is a recombinant fusion protein that binds PCSK9 with picomolar affinity. PCSK9 binds to low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, lerodalcibep-liga increases the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LEROCHOL represents a launch-stage opportunity in a high-stakes, mature therapeutic class with significant competitive headwind. Working on this brand requires strong execution in market access, clinical differentiation, and rapid uptake strategy to compete against entrenched, billion-dollar incumbents.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.